BPC-157 vs. TB-500: Comparing Two Research Peptides

BPC-157 and TB-500 are two of the most frequently referenced research peptides, and they are often studied as a combination. They are, however, distinct compounds with different origins and different mechanisms under investigation.

Origins

BPC-157 is a synthetic 15–amino-acid sequence derived from a fragment of a gastric protein. TB-500 is a synthetic peptide corresponding to a biologically active region of thymosin beta-4 (Tβ4), a naturally occurring protein involved in cytoskeletal organization.

Structure at a glance

• BPC-157 — pentadecapeptide, 15 amino acids, CAS 137525-51-0, formula C₆₂H₉₈N₁₆O₂₂
• TB-500 — synthetic thymosin beta-4 fragment, CAS 77591-33-4, formula C₂₁₂H₃₅₀N₅₆O₇₈S

Pathways studied

Research on BPC-157 has focused on angiogenic and inflammatory signaling and cytoprotection in tissue-model systems. Research on TB-500 has centered on actin regulation and cell migration — thymosin beta-4 is well known in cell biology for sequestering G-actin and influencing cytoskeletal dynamics, which is why TB-500 is studied in cell-migration and wound-model contexts.

Because the two are investigated for partly complementary pathways (vascular/inflammatory signaling for BPC-157, cytoskeletal/migration dynamics for TB-500), they are commonly combined in research blends to study potential additive effects in controlled models.

The combination blend

A BPC-157 + TB-500 blend supplies both peptides in a single research vial. As with any blend, characterization is per-component, and researchers should consult the certificate of analysis for the identity and purity of each constituent. The blend is, like its components, supplied for in vitro laboratory research only.